Ocuphire Pharma, Inc. - Wutah dodolan YoY (TTM) OCUP

Ocuphire Pharma, Inc. (OCUP) is characterized by a pragmatic approach to R&D and transparent control of patent rights. The trailing 12-month sales growth year-over-year on this GURU.Markets chart reached 9169.00, reflecting the current metric level. While growth is supported by the success of Ryzumos and data on APX3330, a revenue deficit is causing cash flow gaps and the depletion of reserves.
Ringkesan rincian data analitis Ocuphire Pharma (OCUP)

Ocuphire Pharma, Inc. (OCUP) expands its business through strategic alliances to bring ophthalmological drugs to market, leveraging high loyalty within the professional community. The year-over-year (YoY) sales trajectory (TTM) measures daily revenue dynamics relative to the previous year, allowing investors to assess the company's fundamental stability and balance risks during sharp market movements by analyzing the amplitude of operational fluctuations.